Longeveron Inc. (LGVN)
NASDAQ: LGVN · IEX Real-Time Price · USD
1.720
-0.100 (-5.49%)
At close: Apr 24, 2024, 4:00 PM
1.680
-0.040 (-2.33%)
After-hours: Apr 24, 2024, 5:34 PM EDT
Company Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan.
The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors.
It is conducting Phase 1, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome.
The company was incorporated in 2014 and is headquartered in Miami, Florida.
Longeveron Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Feb 12, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Mohamed Wa'el Ahmed Hashad |
Contact Details
Address: 1951 Nw 7th Avenue, Suite 520 Miami, Florida 33136 United States | |
| Phone | 305-302-7158 |
| Website | longeveron.com |
Stock Details
| Ticker Symbol | LGVN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001721484 |
| CUSIP Number | 54303L104 |
| ISIN Number | US54303L1044 |
| Employer ID | 47-2174146 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Joshua Michael Hare FACC, M.D. | Co-Founder, Chief Science Officer and Chairman |
| Mohamed Wa'el Ahmed Hashad | Chief Executive Officer and Director |
| Lisa A. Locklear M.B.A. | Executive Vice President and Chief Financial Officer |
| Paul T. Lehr J.D. | International Executive Director, General Counsel and Secretary |
| Dr. Dan Gincel Ph.D. | Senior Vice President of Strategic Collaborations and Scientific Affairs |
| Dr. Nataliya Agafanova M.D. | Chief Medical Officer |
| Elly Ryu | Vice President and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | 8-K | Current Report |
| Apr 17, 2024 | EFFECT | Notice of Effectiveness |
| Apr 17, 2024 | 424B4 | Prospectus |
| Apr 17, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 16, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 11, 2024 | 8-K | Current Report |
| Apr 10, 2024 | 424B3 | Prospectus |
| Apr 10, 2024 | 424B4 | Prospectus |
| Apr 8, 2024 | EFFECT | Notice of Effectiveness |